Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Budget,
Health,
Industry
|
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs.
|
Policies or Program
|
Health,
Industry,
Research and Development,
Science and Technology
|
Engagement with officials on the development of the Canada's Drug Agency and Bill C-64: An Act respecting pharmacare
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Health,
Industry,
Research and Development,
Science and Technology
|
Establish Innovation, Science and Economic Development Canada policies related to research and development of treatments for rare disorders
|
Policies or Program
|
Health
|
Regulatory amendments to the Food and Drugs Act Regulations to implement an orphan drug regulatory framework
|
Regulation
|
Budget,
Health,
Industry,
Research and Development,
Science and Technology
|
Scientific Research and Experimental Development Tax Incentive Program as it pertains to research and development of treatments for rare disorders
|
Policies or Program
|
Budget,
Health,
Industry
|
Share perspectives of the rare disorders patient community on drug pricing issues, specifically regulations and guidelines related to the Patented Medicine Prices Review Board.
|
Policies or Program,
Regulation
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Engagement with officials regarding the Advisory Committee on the Implementation of National Pharmacare on issues related to rare disorder and orphan drug policies in the context of the development of national pharmacare.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Establish Health Canada policies and programs related to orphan drug policy, including part of any national pharmacare program or strategy, to ensure access to essential treatment for rare disorders.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Establish Innovation, Science and Economic Development Canada policies related to research and development of treatments for rare disorders
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicines Regulations, specifically, amendments proposed on December 2, 2017 related to the operations of the PMPRB
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Regulatory amendments to the Food and Drugs Act Regulations to implement an orphan drug regulatory framework
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Scientific Research and Experimental Development Tax Incentive Program as it pertains to research and development of treatments for rare disorders
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Share perspectives of the rare disorders patient community on drug pricing issues, specifically regulations and guidelines related to the Patented Medicine Prices Review Board.
|
Policies or Program,
Regulation
|
Communication techniques that have been used or are expected to be used in the course of the undertaking: